Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
BioNTech, BMS report Phase 2 pumitamig data in NSCLC after immunotherapy progressionOct 26Clinical readoutBioNTech SEBristol Myers SquibbUpdated
BMS posts RELATIVITY-106 liver cancer results; files two new Phase 1/2 trialsOct 16Weekly roundup, 4 itemsBioNTech SEBristol Myers SquibbUpdated
Boehringer Ingelheim registers Phase Ib/II trial testing obrixtamig plus pumitamig in SCLCOct 13Trial updateBioNTech SEBoehringer Ingelheim
Boehringer Ingelheim registers Phase Ib/II trial pairing obrixtamig, pumitamig in SCLCSep 28Trial updateBioNTech SEBoehringer Ingelheim
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca
BioNTech names Guido Oelkers CEO, trims 2026 revenue guidance in Q2 updateAug 4Quarterly updateBioNTech SE
BMS posts PRIME-HCC results; adds SOTYKTU label update, Phase 3 lung trialJul 2Weekly roundup, 7 itemsBristol Myers Squibbcisplatin